Skip to navigationSkip to content
  • A-Z Medicines
  • FAQ
  • Subscribe
Logo: Department of Health, Disability and AgeingLogo: Pharmaceutical Benefits Scheme
medicine search
  • Home
  • PBS Information
    • About the PBS
    • PBS Contacts
    • Latest News
    • Subscribe to PBS News
    • Frequently asked questions
    • Pharmaceutical Benefits Advisory Committee (PBAC)
    • Medicine Status
    • Eighth Community Pharmacy Agreement (8CPA)
    • PBS Process Improvements
    • Biosimilars on the PBS
    • PBS Publications
    • PBS Downloads
    • PBS Reviews
    • PBS Statistics
    • Committees
    • Working Groups
    • Report adverse drug reactions
    • PBS Mobile website
    • PBS Software Developers
  • Browse the PBS
    • New,amended and deleted
    • 60-day prescriptions
    • A-Z medicine listing
    • Biological Medicines
    • Body system
    • Botulinum Toxin Program
    • Continued Dispensing Arrangements
    • Dental Items
    • Efficient Funding of Chemotherapy
    • Growth Hormone Program
    • Highly Specialised Drugs Program
    • IVF Program
    • Manufacturer / Supplier
    • Midwife Items
    • Nurse Practitioner Items
    • Opioid Dependence Treatment Program
    • Optometrical Items
    • Palliative Care Items
    • Prescriber Bag Supplies
    • Repatriation (RPBS)
    • Safety Net early supply
    • Section 100
    • Streamlined Authorities
    • Supply Only
    • Therapeutic group
    • Explanatory notes
      • Fees & Patient Contributions
      • Standard Packs and Prices
      • Extemporaneously-Prepared
    • Price Premiums
      • Brand Premium
      • Therapeutic group premium
      • Special patient contribution
  • For Health Professionals
    • For PBS Prescribers
    • For Pharmacists
  • For Industry
    • How to List on the PBS
    • Pricing Matters
    • Supply Matters
    • PBS Statistics
    • Useful Resources
    • Industry FAQ
    • PBAC Meetings
    • PBAC Guidelines
    • PBS Calendars
    • PBS Forms
    • Health Products Portal
  • News
    • Latest News
    • Subscribe to News Updates
  • Publications & Downloads
    • PBS Publications
    • Downloads
  • Contacts
  • Home/
  • Industry/
  • Listing/
  • Elements/
  • Pbac Meetings/
  • Psd/
  • 2025 03/
  • Elranatamab Psd March 2025

Elranatamab; Solution for subcutaneous injection 44 mg in 1.1 mL (40 mg per mL), Solution for subcutaneous injection 76 mg in 1.9 mL (40 mg per mL); Elrexfio®

Page last updated: 4 July 2025

  • Public Summary Document (PSD) March 2025 PBAC Meeting - (PDF 1.8MB)
  • Public Summary Document (PSD) March 2025 PBAC Meeting - (Word 585KB)

Department of Health, Disability and Ageing

Logo: Department of Health, Disability and Ageing

Pharmaceutical Benefits Scheme

PBS Logo

© Commonwealth of Australia
ABN: 83 605 426 759

PBS Information

  • About the PBS
  • Frequently asked questions
  • Pharmaceutical Benefits Advisory Committee (PBAC)
  • Publications & Downloads
  • PBS Reviews
  • PBS Statistics
  • Report adverse drug reactions
  • PBS Mobile website
  • PBS Software Developers
  • Latest News
  • Subscribe to PBS News
  • PBS Contacts

Browse the PBS

  • New, amended and deleted
  • A-Z medicine listing
  • Repatriation (RPBS)
  • Explanatory notes
  • Body system
  • Dental Items
  • Prescriber Bag Supplies
  • Midwife Items
  • Nurse Practitioner Items
  • Optometrical Items
  • Palliative Care Items
  • Section 100
  • Manufacturer / Supplier
  • Safety Net Scheme
  • Streamlined Authorities
  • Therapeutic Group
  • Browse Price Premiums

For Health Professionals

  • For PBS Prescribers
  • For Pharmacists
  •  
  •  
  • ABOUT
  • About This Site
  • Contact Us
  • Accessibility
  • Privacy
  • Disclaimer
  • Copyright

For Industry

  • How to List on the PBS
  • The Listing Steps
  • Elements of the listing process
  • Participants in the listing process
  • Pricing Matters
  • Pricing of PBS Items
  • Price Disclosure (SPD)
  • PBS Statistics
  • Useful Resources
  • Pharmaceutical Benefits Advisory Committee (PBAC)